Table 1.
Characteristics of the Patients
| Parameter | Number of Patients (Percent)/Median (Range) |
|---|---|
| Age | 61.5 (19–88 years) |
| - 19–49 | 33 (26%) |
| - 50–61 | 29 (23%) |
| - 62–70 | 31 (25%) |
| - 71–88 | 33 (26%) |
| Gender | |
| - Female | 66 (52%) |
| - Male | 60 (48%) |
| WHO | |
| - 0 | 53 (42%) |
| - 1 | 53 (42%) |
| - 2 | 18 (14%) |
| - 3 | 2 (2%) |
| Location | |
| - parotid gland | 73 (58%) |
| - submandibular gland | 53 (42%) |
| Time from surgery to radio- or radiochemotherapy | |
| <9 weeks | 61 (48%) |
| ≥9 weeks | 65 (52%) |
| Clinical nerve palsy | |
| - yes | 33 (26%) |
| - no | 93 (74%) |
| Radicality | |
| - R0 | 64 (51%) |
| - R1 | 51 (48%) |
| - R2 | 11 (9%) |
| Nerve palsy after surgery | |
| - yes | 37 (29%) |
| - no | 89 (71%) |
| Histopathological type | |
| - squamous cell carcinoma | 29 (23%) |
| - adenocarcinoma | 20 (16%) |
| - adenoid cystic | 22 (17%) |
| - undifferentiated carcinoma | 14 (11%) |
| - acinic cell carcinoma | 13 (10%) |
| - other (polymorphus adenocarcinoma, salivary duct carcinoma, mucoepidermoid carcinoma high grade, mucoepidermoid carcinoma intermediate and low grade, myoepitelial carcinoma, carcinoma ex pleomorfic adenoma | 4 (3%), 8 (6%), 8 (6%), 3 (2%), 3 (2%), 2 (2%) |
| Neuroinvasion | |
| - yes | 41 (33%) |
| - no | 85 (67%) |
| Angioinvasion | |
| - yes | 18 (14%) |
| - no | 108 (86%) |
| TNM Stage | |
| I | 18 (14%) |
| II | 29 (23%) |
| III | 27 (21%) |
| IVab | 52 (41%) |
| T1 | 22 (17%) |
| T2 | 39 (31%) |
| T3 | 30 (24%) |
| T4 | 35 (28%) |
| N0 | 83 (66%) |
| N 1–3 | 43 (34%) |
| Technique of radiation therapy | |
| - 2D | 26 (21%) |
| - 3D | 29 (23%) |
| - IMRT | 71 (56%) |
| Dose | 60 (40–72) Gy |
| <60Gy | 28 (22%) |
| ≥60Gy | 98 (78%) |
| Chemotherapy | |
| - yes | 19 (15%) |
| - no | 107 (85%) |
| Initial level of hemoglobin | |
| <12.5mg/dL | 10 (25%) |
| ≥12.5mg/dL | 30 (75%) |
| Tumor volume | 54.1 cm3 (3.7–197.7) cm3 |
| ≤10cm3 | 20 (24%) |
| 10.1–50cm3 | 28 (33%) |
| 50.1–100cm3 | 24 (29%) |
| >100cm3 | 12 (14%) |
| Irradiation area | |
| - only surgical bed with margin | 25 (20%) |
| - surgical bed + lnd. group I–II | 27 (21%) |
| - surgical bed + unilateral lnd. | 45 (36%) |
| - surgical bed + bilateral lnd | 28 (22%) |
| Tumor bed volume (dose ≥ 60Gy) | 151.5cm3 (43.6–392.1)cm3 |
| ≤100cm3 | 16 (19%) |
| 100.1–200cm3 | 33 (31%) |
| 200.1–300cm3 | 18 (21%) |
| >300cm3 | 17 (20%) |
| Elective area volume (dose ≥ 50Gy) | 278 cm3 (103.2–633.4) cm3 |
| ≤ 150cm3 | 42 (50%) |
| 150.1–300cm3 | 19 (23%) |
| 300.1–450cm3 | 12 (14%) |
| 450.1–600cm3 | 8 (10%) |
| >600cm3 | 3 (4%) |
Abbreviations: R0, radical surgery; R1, microscopic nonradical surgery, R2, macroscopic nonradical surgery; lnd, lymphadenectomy.